Skip to content

Press Releases: Senior LifeSphere Product Leader to Speak about ICH E6(R3) at SCOPE Summit 2022

Industry veteran Dario Lirio to address concerns and provide insights towards the newly drafted clinical trial regulation

MIAMI, FL, January 28, 2022 – ArisGlobal, the leading provider of life sciences software that automates core drug development with its end-to-end technology platform LifeSphere®, today announced their podium presentation and attendance at the Summit for Clinical Trials Operations Executives (SCOPE) in Orlando, FL, February 7-10, 2022.

Dario Lirio, Senior Director of Clinical Product Management will lead the leading life science technology’s podium presentation centered around Risk Based Quality Management.

Wednesday, February 9th, 10:10-10:25am

• Session: Outlook for Risk Based Monitoring with ICH E6(R3) Arriving

Expected to land soon, the public draft of ICH E6(R3) brings renewed focus to Risk Based Monitoring in clinical trials. Dario Lirio provides perspective on how technology can enable operations professionals to prepare for the new guidance. Will the new ICH E6(R3) draft guidance bring more clarity or add new implementation challenges to adopting risk-based practices?

Dario, an 18-year veteran of life sciences technology shares that he is eager to speak to an audience of peers at SCOPE, offering that, “SCOPE is a great environment to meet people from different organizations, and also to hear about their initiatives to solve problems and make the clinical industry community stronger.”

LifeSphere Clinical, the core Clinical offering by ArisGlobal, will be appearing virtually at the show.

Webinar: The Future of Safety Signal Analytics is Now With LifeSphere Clarity   Learn more